Drug intelligence / Profile preview

triamcinolone + nepafenac

Development stage
Phase 3
Lead developer
Harrow
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Intravitreal, Ophthalmic
01

Overview

Triamcinolone + nepafenac is a combination of two pharmaceutical agents used primarily in ophthalmology. Triamcinolone is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory properties, often administered via intravitreal injection to reduce inflammation and edema in the posterior segment of the eye. Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID) formulated as an ophthalmic suspension; it acts as a prodrug that is converted by intraocular hydrolases to amfenac, which inhibits cyclooxygenase (COX) enzymes and reduces prostaglandin synthesis, thereby decreasing ocular pain and inflammation. This combination may be considered for conditions such as cystoid macular edema or post-surgical inflammation where both steroidal and nonsteroidal anti-inflammatory effects are desired[1][2][3]. However, clinical studies have not consistently shown added benefit from combining these agents compared to monotherapy[1].

02

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on triamcinolone + nepafenac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on triamcinolone + nepafenac.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call